Document Detail

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
MedLine Citation:
PMID:  17216565     Owner:  NLM     Status:  MEDLINE    
Twenty-five years ago, we reported the production of the monoclonal antibody, anti-Tac that identifies the IL-2 receptor alpha subunit and blocks the interaction of IL-2 with this growth factor receptor. In 1997, daclizumab (Zenapax), the humanized form of this antibody, was approved by the FDA for use in the prevention of renal allograft rejection. In addition, we demonstrated that daclizumab is of value in the treatment of patients with noninfectious uveitis, multiple sclerosis, and the neurological disease human T-cell lymphotropic virus I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Others demonstrated therapeutic efficacy with daclizumab in patients with pure red cell aplasia, aplastic anemia, and psoriasis. Thus, translation of basic insights concerning the IL-2/IL-2 receptor system obtained using the monoclonal antibody daclizumab provided a useful strategy for the prevention of organ allograft rejection and the treatment of patients with select autoimmune diseases or T-cell leukemia/lymphoma.
Thomas A Waldmann
Related Documents :
15808695 - Role of cd4+ and cd8+ t cells in the rejection of heart or islet xenografts in recipien...
8128405 - Development of immunological assays to monitor pulmonary allograft rejection.
9502425 - Fate of antigen in xenotransplantation: implications for acute vascular rejection and a...
1281565 - Induction of long-term survival of rat skin allografts by a novel, highly efficient ant...
2174295 - An enzyme-linked immunosorbent assay for detection of antibodies to maedi-visna virus i...
2200175 - Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review     Date:  2007-01-11
Journal Detail:
Title:  Journal of clinical immunology     Volume:  27     ISSN:  0271-9142     ISO Abbreviation:  J. Clin. Immunol.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-08     Completed Date:  2007-05-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8102137     Medline TA:  J Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-18     Citation Subset:  IM    
Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH Building 10, Bethesda, Maryland 20892-1374, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / immunology,  pharmacology,  therapeutic use*
Autoimmune Diseases / drug therapy*
Binding, Competitive / immunology
Graft Rejection / immunology,  prevention & control*
Immunoglobulin G / immunology,  pharmacology,  therapeutic use*
Immunosuppressive Agents / therapeutic use*
Interleukin-2 / antagonists & inhibitors,  immunology
Interleukin-2 Receptor alpha Subunit / antagonists & inhibitors,  immunology
Leukemia / drug therapy*,  metabolism
Leukemia-Lymphoma, Adult T-Cell / drug therapy
Paraparesis, Tropical Spastic / drug therapy
Receptors, Interleukin-2 / antagonists & inhibitors,  drug effects*,  immunology
Uveitis / drug therapy
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Interleukin-2; 0/Interleukin-2 Receptor alpha Subunit; 0/Receptors, Interleukin-2; 152923-56-3/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Discordance among blastomeres renders preimplantation genetic diagnosis for aneuploidy ineffective.
Next Document:  The expression of retinoic acid receptors in lymph nodes of young children and the effect of all-tra...